RecruitingLiver Diseases, Alcoholic
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Eligible age
18–70 yrs
Accepts
All genders
Locations
16 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Participant must be 18 to 70 years of age inclusive, at the time of screening. (Participants in South Korea must be greater than or equal to \[\>=\] 19 years of age and participants in Japan must be \>= 20 years of age.)
- ✓ Capable of giving signed informed consent prior to the performance of any study-specific procedures.
- ✓ Able and willing to comply with all study assessments and adhere to the protocol schedule of activities.
- ✓ In the opinion of the investigator, there is a history of alcohol consumption compatible with either ALD or Met ALD.
- ✓ A female participant is eligible to participate after meeting additional pre-defined criteria.
- ✓ Participants must meet predefined stable use requirements of concomitant medications based on study criteria.
- ✓ Participant has advanced chronic liver disease
You may not qualify if…
- ✕ Meeting any definition of organ system failure as defined by the North American Consortium for Study of End-stage Liver Disease (NACSELD)
- ✕ Exceeding pre-defined biochemical parameters for ALT, AST, ALP, Platelets, INR, Albumin, eGFR, UACR or HbA1c. Other primary causes of liver disease based on study criteria.
- ✕ Current malignancy (except for basal cell carcinoma or uterine carcinoma-in-situ) at screening. Participants under evaluation for possible malignancy at screening are not eligible.
- ✕ Prior organ transplant (except for corneal transplants).
- ✕ Chronic or acute, including partial, known portal vein thrombosis.
- ✕ Prior Transjugular Intrahepatic Portosystemic Shunt (TIPSS) insertion.
- ✕ Any acute cardiovascular event including myocardial infarction, unstable angina, symptomatic heart failure, or cerebrovascular accident in the 6 months prior to screening.
- ✕ Poorly controlled hypertension
Where it's recruiting
Source: ClinicalTrials.gov · NCT06613698 · last updated 2026-11-13